Literature DB >> 28621828

Progress in the synthesis and biological evaluation of lipid A and its derivatives.

Jian Gao1, Zhongwu Guo2.   

Abstract

n class="Chemical">Lipid A is one of the core structures of bacterial n class="Chemical">lipopolysaccharides (LPSs), and it is mainly responsible for the strong immunostimulatory activities of LPS through interactions with the Toll-like receptors and other molecules in the human immune system. To obtain structurally homogeneous and well-defined lipid As and its derivatives in quantities meaningful for various biological studies and applications, their chemical synthesis has become a focal point. This review has provided a survey of significant progresses made in the synthesis of lipid A, and its derivatives that carry diverse saturated and unsaturated lipids, have the phosphate group at its reducing end replaced with a more stable phosphate or carboxyl group, or lack the reducing end phosphate or both phosphate groups, as well as progresses in the synthesis of LPS analogs and other lipid A conjugates. These synthetic molecules have facilitated the elucidation of the structure-activity relationships of lipid A useful for the design and development of lipid A based therapeutics, such as those utilized to treat sepsis, and other medical applications, for example the use of monophosphoryl lipid A as a carrier molecule for the study of fully synthetic self-adjuvanting conjugate vaccines. These topics are also briefly covered in the current review.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  adjuvant; immunostimulant; immunotherapy; lipid A; lipopolysaccharide; synthesis

Mesh:

Substances:

Year:  2017        PMID: 28621828      PMCID: PMC5732894          DOI: 10.1002/med.21447

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  114 in total

Review 1.  Toll receptors, CD14, and macrophage activation and deactivation by LPS.

Authors:  Marina A Dobrovolskaia; Stefanie N Vogel
Journal:  Microbes Infect       Date:  2002-07       Impact factor: 2.700

2.  Deacylation of structurally diverse lipopolysaccharides by human acyloxyacyl hydrolase.

Authors:  A L Erwin; R S Munford
Journal:  J Biol Chem       Date:  1990-09-25       Impact factor: 5.157

Review 3.  Pathogenetic mechanisms of septic shock.

Authors:  J E Parrillo
Journal:  N Engl J Med       Date:  1993-05-20       Impact factor: 91.245

4.  Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines.

Authors:  Yanbin Pan; Peter Chefalo; Nancy Nagy; Clifford Harding; Zhongwu Guo
Journal:  J Med Chem       Date:  2005-02-10       Impact factor: 7.446

5.  Chemical structure of lipid A from Helicobacter pylori strain 206-1 lipopolysaccharide.

Authors:  Y Suda; T Ogawa; W Kashihara; M Oikawa; T Shimoyama; T Hayashi; T Tamura; S Kusumoto
Journal:  J Biochem       Date:  1997-06       Impact factor: 3.387

6.  Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion.

Authors:  A B Schromm; K Brandenburg; H Loppnow; A P Moran; M H Koch; E T Rietschel; U Seydel
Journal:  Eur J Biochem       Date:  2000-04

Review 7.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

8.  The role of cytophilic IgG3 antibody in T cell-mediated resistance to infection with the extracellular bacterium, Pseudomonas aeruginosa.

Authors:  R B Markham; G B Pier; J R Schreiber
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

Review 9.  Lipopolysaccharide: Biosynthetic pathway and structure modification.

Authors:  Xiaoyuan Wang; Peter J Quinn
Journal:  Prog Lipid Res       Date:  2009-10-06       Impact factor: 16.195

10.  Burkholderia cenocepacia lipopolysaccharide, lipid A, and proinflammatory activity.

Authors:  Anthony De Soyza; Charles D Ellis; C M Anjam Khan; Paul A Corris; Raquel Demarco de Hormaeche
Journal:  Am J Respir Crit Care Med       Date:  2004-03-24       Impact factor: 21.405

View more
  7 in total

Review 1.  TLR-4 Signaling vs. Immune Checkpoints, miRNAs Molecules, Cancer Stem Cells, and Wingless-Signaling Interplay in Glioblastoma Multiforme-Future Perspectives.

Authors:  Jakub Litak; Cezary Grochowski; Joanna Litak; Ida Osuchowska; Krzysztof Gosik; Elżbieta Radzikowska; Piotr Kamieniak; Jacek Rolinski
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

Review 2.  Pathological and Therapeutic Approach to Endotoxin-Secreting Bacteria Involved in Periodontal Disease.

Authors:  Rosalia Marcano; M Ángeles Rojo; Damián Cordoba-Diaz; Manuel Garrosa
Journal:  Toxins (Basel)       Date:  2021-07-29       Impact factor: 4.546

3.  Fully synthetic Mincle-dependent self-adjuvanting cancer vaccines elicit robust humoral and T cell-dependent immune responses and protect mice from tumor development.

Authors:  Xiang Luo; Qinghai Lian; Wenwei Li; Liqing Chen; Renyu Zhang; Deying Yang; Lingqiang Gao; Xiaoxiao Qi; Zhongqiu Liu; Guochao Liao
Journal:  Chem Sci       Date:  2021-12-01       Impact factor: 9.825

4.  MUC1 Specific Immune Responses Enhanced by Coadministration of Liposomal DDA/MPLA and Lipoglycopeptide.

Authors:  Jing-Jing Du; Shi-Hao Zhou; Zi-Ru Cheng; Wen-Bo Xu; Ru-Yan Zhang; Long-Sheng Wang; Jun Guo
Journal:  Front Chem       Date:  2022-02-04       Impact factor: 5.221

5.  Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection.

Authors:  Robert E Haupt; Erin M Harberts; Robert J Kitz; Shirin Strohmeier; Florian Krammer; Robert K Ernst; Matthew B Frieman
Journal:  Vaccine       Date:  2021-08-03       Impact factor: 4.169

Review 6.  Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines.

Authors:  Qingjiang Li; Zhongwu Guo
Journal:  Molecules       Date:  2018-06-29       Impact factor: 4.411

Review 7.  New Insights of Anti-Hyperglycemic Agents and Traditional Chinese Medicine on Gut Microbiota in Type 2 Diabetes.

Authors:  Yanxia Chen; Mian Wang
Journal:  Drug Des Devel Ther       Date:  2021-11-30       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.